Hypothesis: Aging Shifts cfDNA Release From Apoptotic Nucleosome Trimming to Active Vesicular Preservation, Altering Fragment Size and Methylation Clock Readouts

Mechanism

With age, cells experience progressive changes in nuclear lamina stiffness and chromatin organization that affect how DNA is released into circulation. In youth, the predominant source of plasma cfDNA is apoptotic nucleosomes trimmed by caspase‑activated DNase to ~166 bp, reflecting the protected nucleosome core. As lamin A/C accumulates and the nuclear envelope becomes more rigid, chromatin becomes less accessible to apoptotic nucleases, favoring alternative release pathways. Specifically, aging cells increase shedding of exosomes and microvesicles that encapsulate intact nucleosome‑protected DNA (~166‑170 bp) without enzymatic trimming. This shift results in a higher proportion of terminal cfDNA fragments that retain the canonical nucleosome size, while overall cfDNA concentration rises due to increased secretory activity.

The mechanistic link to methylation clocks lies in the fact that vesicular packaging preferentially preserves DNA from lamina‑associated domains (LADs) and heterochromatic regions, which are enriched for age‑related methylation changes (e.g., EPIC clock sites). Apoptotic trimming, by contrast, biases toward euchromatic, transcriptionally active regions that are less informative for epigenetic age. Consequently, the cfDNA methylation signal measured in plasma becomes a weighted average of two sources: (1) apoptotic, short‑fragment, euchromatic DNA (lower methylation age signal) and (2) vesicular, nucleosome‑length, heterochromatic DNA (higher methylation age signal).

Prediction

If this model is correct, then across the human lifespan:

• The ratio of 166‑170 bp cfDNA fragments to shorter (<150 bp) fragments will increase with biological age, independent of chronological age.
• cfDNA methylation age (e.g., Horvath or Hannum clock adapted to cfDNA) will correlate positively with the proportion of nucleosome‑length fragments and negatively with the proportion of apoptotic short fragments.
• Plasma markers of exosome release (e.g., CD63‑positive vesicles, Annexin V‑negative cfDNA) will rise with age, while markers of apoptosis (cleaved caspase‑3, nucleosome‑free DNA) will plateau or decline.
• Perturbing nuclear lamina stiffness (e.g., lamin A/C knockdown in cultured senescent cells) will reduce the secretion of nucleosome‑length cfDNA and shift the fragment distribution toward shorter sizes, accompanied by a decrease in cfDNA‑derived methylation age.

Experimental Design

1. Cohort: Recruit 200 participants stratified by decade (20‑80 y) and measure biological age using the PhenoAge clinical biomarker.
2. Plasma Processing: Isolate cfDNA using standardized low‑bind tubes and quantify total cfDNA concentration.
3. Fragmentomics: Perform low‑coverage whole‑genome sequencing to generate fragment size histograms; calculate the % of reads in 166‑170 bp window vs <150 bp window.
4. Methylation Profiling: Apply targeted bisulfite sequencing of CpG sites from the Horvath clock; compute cfDNA methylation age.
5. Assays: Measure plasma exosome concentration (NTA, CD63 ELISA), apoptotic caspase‑3 activity, and nucleosome‑free DNA (using a mono‑nucleosome‑specific assay).
6. Statistical Analysis: Use multivariate regression to test whether fragment‑size ratio predicts cfDNA methylation age after adjusting for chronological age, sex, and cell‑type deconvolution estimates.
7. Perturbation: Treat primary fibroblasts from young donors with progerin (lamin A/C mutant) or siRNA against LMNA; collect conditioned media and repeat steps 2‑5.

Potential Confounders and Controls

• Exercise or acute inflammation: Standardize sample collection after 30 min rest and record recent physical activity.
• Cancer or subclinical disease: Exclude participants with abnormal CBC, elevated CRP, or positive liquid biopsy screens.
• Pre‑analytical variation: Process all samples within 2 h of draw, use identical centrifugation protocols, and include spike‑in controls for extraction efficiency.
• Cell‑type shifts: Perform cfDNA‑based deconvolution (e.g., using methylation signatures of major blood lineages) to adjust for changes in leukocyte composition.

Falsifiability

If longitudinal data show no significant relationship between the nucleosome‑length cfDNA fraction and cfDNA methylation age, or if manipulation of nuclear lamina fails to alter fragment distribution, the hypothesis would be refuted. Conversely, confirming the predicted correlations would support a model in which age‑dependent changes in nuclear mechanics steer cfDNA release toward vesicular preservation, thereby shaping both fragmentomics and epigenetic clocks in plasma.